They involved PD-0325901 (mirdametinib), trametinib, dabrafenib, and MEK162 (binimetinb) in phase 1 and 2 studies and included individuals with NF1-associated plexiform neurofibromas and other cancers harboring V600 mutations or RAS/RAF/MEK activated tumors. Here, MAP2K7 is linked to cancer.